CorMedix Inc. (CRMD): Price and Financial Metrics
CRMD Price/Volume Stats
Current price | $3.80 | 52-week high | $6.09 |
Prev. close | $3.81 | 52-week low | $2.57 |
Day low | $3.64 | Volume | 447,600 |
Day high | $3.88 | Avg. volume | 444,298 |
50-day MA | $3.37 | Dividend yield | N/A |
200-day MA | $3.77 | Market Cap | 208.29M |
CRMD Stock Price Chart Interactive Chart >
CRMD POWR Grades
- CRMD scores best on the Sentiment dimension, with a Sentiment rank ahead of 55.44% of US stocks.
- CRMD's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- CRMD ranks lowest in Quality; there it ranks in the 3rd percentile.
CRMD Stock Summary
- The ratio of debt to operating expenses for CORMEDIX INC is higher than it is for about just 5.88% of US stocks.
- CRMD's price/sales ratio is 6,588.07; that's higher than the P/S ratio of 99.93% of US stocks.
- As for revenue growth, note that CRMD's revenue has grown -67.75% over the past 12 months; that beats the revenue growth of merely 3.1% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to CORMEDIX INC, a group of peers worth examining would be VHC, SERA, SLGC, XOS, and DYAI.
- Visit CRMD's SEC page to see the company's official filings. To visit the company's web site, go to www.cormedix.com.
CRMD Valuation Summary
- In comparison to the median Healthcare stock, CRMD's price/earnings ratio is 117.84% lower, now standing at -5.2.
- Over the past 166 months, CRMD's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for CRMD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CRMD | 2023-12-29 | 6870.0 | 2.5 | -5.2 | -3.9 |
CRMD | 2023-12-28 | 7070.0 | 2.5 | -5.3 | -4.0 |
CRMD | 2023-12-27 | 7126.7 | 2.6 | -5.4 | -4.1 |
CRMD | 2023-12-26 | 7163.3 | 2.6 | -5.4 | -4.1 |
CRMD | 2023-12-22 | 6850.0 | 2.5 | -5.2 | -3.8 |
CRMD | 2023-12-21 | 6596.7 | 2.4 | -5.0 | -3.7 |
CRMD Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at 36.19%.
- Its 2 year net cashflow from operations growth rate is now at -35.51%.
- Its 2 year cash and equivalents growth rate is now at 267.79%.
The table below shows CRMD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 0.092103 | -24.07125 | -29.28374 |
2022-06-30 | 0.123374 | -23.57935 | -30.99939 |
2022-03-31 | 0.110312 | -21.20875 | -28.02748 |
2021-12-31 | 0.190936 | -21.15522 | -28.21023 |
2021-09-30 | 0.190254 | -21.21935 | -26.50618 |
2021-06-30 | 0.245186 | -23.02867 | -24.53757 |
CRMD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CRMD has a Quality Grade of F, ranking ahead of 0.4% of graded US stocks.
- CRMD's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
- ADAP, FBRX, and IDXX are the stocks whose asset turnover ratios are most correlated with CRMD.
The table below shows CRMD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.004 | 0.132 | -5.939 |
2021-03-31 | 0.005 | 0.141 | -8.398 |
2020-12-31 | 0.007 | 0.144 | -6.360 |
2020-09-30 | 0.007 | 0.070 | -5.242 |
2020-06-30 | 0.006 | -0.103 | -3.741 |
2020-03-31 | 0.007 | -0.006 | -2.141 |
CRMD Price Target
For more insight on analysts targets of CRMD, see our CRMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $21.25 | Average Broker Recommendation | 1.5 (Moderate Buy) |
CorMedix Inc. (CRMD) Company Bio
CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.
Latest CRMD News From Around the Web
Below are the latest news stories about CORMEDIX INC that investors may wish to consider to help them evaluate CRMD as an investment opportunity.
CorMedix Inc. Announces Appointment of Chief Legal OfficerBERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no |
CorMedix Inc. Announces Partnership With The Leapfrog Group– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog’s Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other pur |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! |
CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved DefenC |
Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities in Q3 2023Net Loss Widens as Company Prepares for Potential FDA Approval of DefenCath |
CRMD Price Returns
1-mo | 14.80% |
3-mo | 7.95% |
6-mo | 4.68% |
1-year | 9.83% |
3-year | -61.81% |
5-year | -50.33% |
YTD | 1.06% |
2023 | -10.90% |
2022 | -7.25% |
2021 | -38.76% |
2020 | 2.06% |
2019 | 12.87% |
Continue Researching CRMD
Want to do more research on CorMedix Inc's stock and its price? Try the links below:CorMedix Inc (CRMD) Stock Price | Nasdaq
CorMedix Inc (CRMD) Stock Quote, History and News - Yahoo Finance
CorMedix Inc (CRMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...